EIF2A and cholangiocarcinoma: Salubrinal treatment, a selective inhibitor of eIF2α, promoted the phosphorylation of eIF2α and the protein levels of ATF4 in QBC939 and RBE cells (Figure 2A), indicating that salubrinal can inhibit the activity of eIF2α in human CCA cells.